IDEX CORP /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IDEX CORP /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.46B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.27B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.27B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $3.18B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.76B | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $614.82M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $581.11M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $561.25M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $594.46M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $606.00M | Feb 25, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.46B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.27B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.27B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $3.18B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.76B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $2.35B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $2.49B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $2.48B | Feb 25, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $499.80M | Feb 19, 2016 |
| FY2015 | Sep 30, 2015 | $503.79M | Feb 19, 2016 |
| FY2015 | Jun 30, 2015 | $514.88M | Feb 19, 2016 |
| FY2015 | Mar 31, 2015 | $502.20M | Feb 19, 2016 |
| FY2015 | Dec 31, 2014 | $523.90M | Feb 19, 2016 |
| FY2015 | Sep 30, 2014 | $533.18M | Feb 19, 2016 |
| FY2015 | Jun 30, 2014 | $546.69M | Feb 19, 2016 |
| FY2015 | Mar 31, 2014 | $544.00M | Feb 19, 2016 |
| FY2014 | Dec 31, 2013 | $520.62M | Feb 23, 2015 |
| FY2014 | Sep 30, 2013 | $490.62M | Feb 23, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.54B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.45B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.45B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.43B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.22B | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $269.17M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $251.50M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $234.80M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $271.96M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $266.89M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $483.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $505.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $596.10M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $586.90M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $449.40M | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $101.07M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $103.85M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $70.86M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $102.00M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $96.85M | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $699.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $677.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $732.50M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $751.40M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $637.00M | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $138.97M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $131.21M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $110.59M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $139.94M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $134.17M | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $67.40M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $68.40M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $61.40M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $50.10M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $48.20M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $56.40M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $48.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $42.40M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $39.40M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $818.80M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $758.70M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $703.50M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $652.70M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $578.20M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $494.90M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $525.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $536.72M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $524.94M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $492.40M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $680.40M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $668.10M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $716.70M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $557.40M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $565.30M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $569.30M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $528.10M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $479.35M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $432.75M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $399.92M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.60M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $65.10M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $89.90M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $68.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $72.70M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $51.60M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $50.90M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $56.09M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $43.86M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $38.24M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.93B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $6.75B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $5.87B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $5.51B | Feb 22, 2024 |
| FY2023 | Dec 31, 2021 | $4.92B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $4.41B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $3.81B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $3.47B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $3.40B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $3.15B | Feb 28, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.90B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.95B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.32B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.47B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $2.11B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.87B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $1.55B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.48B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $1.51B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.61B | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.03B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.79B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.54B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.04B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $2.80B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $2.54B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $2.26B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.99B | Feb 21, 2020 |
| FY2019 | Dec 31, 2017 | $1.89B | Feb 21, 2020 |
| FY2019 | Dec 31, 2016 | $1.54B | Feb 21, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.41B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.25B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $2.84B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $2.64B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.17B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $1.90B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $1.78B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.70B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $1.70B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $1.63B | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.50B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $4.23B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.93B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.53B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $3.13B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $2.84B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $2.62B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.34B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $2.06B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.83B | Feb 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $580.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $620.80M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $534.30M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $430.20M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $855.40M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.03B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $632.58M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $466.41M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $375.95M | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $235.96M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.83B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.97B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.33B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.48B | Feb 22, 2024 |
| FY2018 | Dec 31, 2018 | $851.08M | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $862.19M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.02B | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | $847.44M | Feb 23, 2017 |
| FY2015 | Dec 31, 2014 | $865.63M | Feb 19, 2016 |
| FY2014 | Dec 31, 2013 | $773.88M | Feb 23, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 25, 2021 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $212.60M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $205.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $190.70M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $177.40M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $161.10M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $151.80M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $147.20M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $127.48M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $111.17M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $102.65M | Feb 28, 2019 |